COURTNEY LUNA: Open Payments
NPI 1376243923 · OVERLAND PARK, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,676 in 80 payments from 23 companies in 2025. Trend: 2023 $659 · 2024 $1,314 · 2025 $1,676
Food & beverage: $1,676
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 19 | $421 |
| GENZYME CORPORATION | 12 | $240 |
| GlaxoSmithKline, LLC. | 11 | $232 |
| Novartis Pharmaceuticals Corporation | 5 | $111 |
| Amgen Inc. | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Grifols USA, LLC | 2 | $63 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Azurity Pharmaceuticals, Inc. | 2 | $37 |
Products named: DUPIXENT, FASENRA, TRELEGY ELLIPTA, NUCALA, TEZSPIRE, Rhapsido, NEFFY, Xolair.
Industry payments across KS — which companies pay providers there.
